Nanoplasmonic Rapid Antimicrobial‐Resistance Point‐of‐Care Identification Device: RAPIDx
Advanced Healthcare Materials · 2025-01 · 14 (1)
DOI: 10.1002/adhm.202402044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 29.08.2024. Verfasst von Jong-Hwan Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California Berkeley, Berkeley, CA, 94720, USA. Hauptthemen laut MEDLINE: Point-of-Care Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: NIAID NIH HHS, NIH HHS, Air Force Office of Scientific Research.
Abstract (Originalsprache)
The emergence of antibiotic resistance has become a global health crisis, and everyone must arm themselves with wisdom to effectively combat the “silent tsunami” of infections that are no longer treatable with antibiotics. However, the overuse or inappropriate use of unnecessary antibiotics is still routine for administering them due to the unavailability of rapid, precise, and point‐of‐care assays. Here, a r apid a ntimicrobial‐resistance p oint‐of‐care i dentification d evice (RAPIDx) is reported for the accurate and simultaneous identification of bacterial species (genotype) and target enzyme activity (phenotype). First, a contamination‐free active target enzyme is extracted via the photothermal lysis of preconcentrated bacteria cells on a nanoplasmonic functional layer on‐chip. Second, the rapid, precise identification of pathogens is achieved by the photonic rolling circle amplification of DNA on a chip. Third, the simultaneous identification of bacterial species (genotype) and target enzyme activity (phenotype) is demonstrated within a sample‐to‐answer 45 min operation via the RAPIDx. It is believed that the RAPIDx will be a valuable method for solving the bottleneck of employing on‐chip nanotechnology for antibiotic‐resistant bioassay and other infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of California Berkeley, Berkeley, CA, 94720, USA.
- Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, 34114, South Korea.
- Department of Mechanical Engineering, Hanbat National University, Daejeon, 34158, South Korea.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
- Division of Infectious Disease and Vaccinology, School of Public Health, University of California, Berkeley, CA, 94720, USA.
- Departments of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SE-751 08, Sweden.
ORCID-Profile: Jong-Hwan Lee, Luke P Lee
Förderung
- NIAID NIH HHS
- NIH HHS
- Air Force Office of Scientific Research
- National Institutes of Health
Zitieren
APA
Lee, J. H., Song, J., Hong, S., Kim, Y., Song, M., Cho, B., Wu, T., Riley, L. W., Landegren, U., & Lee, L. P. (2025). Nanoplasmonic Rapid Antimicrobial‐Resistance Point‐of‐Care Identification Device: RAPIDx. Advanced Healthcare Materials, 14(1). https://doi.org/10.1002/adhm.202402044
Vancouver
Lee JH, Song J, Hong S, Kim Y, Song M, Cho B, et al. Nanoplasmonic Rapid Antimicrobial‐Resistance Point‐of‐Care Identification Device: RAPIDx. Advanced Healthcare Materials. 2025;14(1). doi:10.1002/adhm.202402044
BibTeX
@article{Lee2025,
author = {Lee, Jong-Hwan and Song, Jihwan and Hong, SoonGweon and Kim, Yun and Song, Minsun and Cho, Byungrae and Wu, Tiffany and Riley, Lee W and Landegren, Ulf and Lee, Luke P},
title = {Nanoplasmonic Rapid Antimicrobial‐Resistance Point‐of‐Care Identification Device: RAPIDx},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {1},
doi = {10.1002/adhm.202402044}
}
EUVIMED